Walleye Trading’s Corbus Pharmaceuticals CRBP Stock Holding History

Walleye Trading’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-237	Closed	-$13K	–	4645
2020 Q3	$13K	Buy	+237	New	+$42.9K	﹤0.01%	3879

Other funds holding CRBP

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Walleye Trading's CRBP Position: Q1 2026 in Review

Walleye Trading sold out of Corbus Pharmaceuticals (CRBP) in Q1 2026, closing a stake of 15,851 shares — an estimated $129K sold.

Walleye Trading first reported a position in CRBP in Q2 2016 and held it in 3 quarters. The position peaked at $129K in Q4 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

Walleye Trading reported no remaining Corbus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Walleye Trading sold 15,851 Corbus Pharmaceuticals shares in Q1 2026, an estimated $129K.
Walleye Trading first reported a position in Corbus Pharmaceuticals in Q2 2016 and held it in 3 quarters.
Walleye Trading's Corbus Pharmaceuticals position peaked at $129K in Q4 2025.
107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.